Bayer Aktiengesellschaft (BAYRY)
OTCMKTS · Delayed Price · Currency is USD
11.34
+0.29 (2.62%)
At close: May 20, 2026
Bayer Aktiengesellschaft Revenue
Bayer Aktiengesellschaft had revenue of 13.41B EUR in the quarter ending March 31, 2026, a decrease of -2.42%. This brings the company's revenue in the last twelve months to 45.24B, down -2.87% year-over-year. In the year 2025, Bayer Aktiengesellschaft had annual revenue of 45.58B, down -2.21%.
Revenue (ttm)
45.24B EUR
Revenue Growth
-2.87%
P/S Ratio
0.86
Revenue / Employee
515.54K EUR
Employees
87,757
Market Cap
44.82B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 45.58B | -1.03B | -2.21% |
| Dec 31, 2024 | 46.61B | -1.03B | -2.16% |
| Dec 31, 2023 | 47.64B | -3.10B | -6.11% |
| Dec 31, 2022 | 50.74B | 6.66B | 15.10% |
| Dec 31, 2021 | 44.08B | 2.68B | 6.48% |
| Dec 31, 2020 | 41.40B | -2.15B | -4.93% |
| Dec 31, 2019 | 43.55B | 6.80B | 18.52% |
| Dec 31, 2018 | 36.74B | 1.73B | 4.93% |
| Dec 31, 2017 | 35.02B | 72.00M | 0.21% |
| Dec 31, 2016 | 34.94B | -11.14B | -24.18% |
| Dec 31, 2015 | 46.09B | 4.75B | 11.48% |
| Dec 31, 2014 | 41.34B | 1.18B | 2.94% |
| Dec 31, 2013 | 40.16B | 416.00M | 1.05% |
| Dec 31, 2012 | 39.74B | 3.21B | 8.80% |
| Dec 31, 2011 | 36.53B | 1.44B | 4.10% |
| Dec 31, 2010 | 35.09B | 3.92B | 12.58% |
| Dec 31, 2009 | 31.17B | -1.75B | -5.32% |
| Dec 31, 2008 | 32.92B | 533.00M | 1.65% |
| Dec 31, 2007 | 32.39B | 32.19B | 16,422.96% |
| Dec 31, 2006 | 196.00M | -24.51B | -99.21% |
| Dec 31, 2005 | 24.70B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Vaxart | 255.61M |
| Glass House Brands | 177.68M |
| Elite Pharmaceuticals | 140.12M |
| Tian'an Technology Group | 2.12M |
| Northwest Biotherapeutics | 1.50M |
| Comjoyful International Company | 564.97K |
Bayer Aktiengesellschaft News
- 20 hours ago - Bayer upgraded to Buy from Hold at DZ Bank - TheFly
- 1 day ago - Bayer granted priority review for asundexian by FDA - TheFly
- 1 day ago - Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention - Nasdaq
- 1 day ago - Bayer (BAYRY) Receives FDA Priority Review for Asundexian in Stroke Prevention - GuruFocus
- 1 day ago - Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack - Business Wire
- 2 days ago - EQS-PVR: Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 2 days ago - Bayer (BAYRY) Settles Toxic Contamination Claims for $133M - GuruFocus
- 2 days ago - Bayer agrees to pay $133 million for PCB cleanup in two states - Reuters